Please use this identifier to cite or link to this item:
|Title:||Blunted Response to Combination Antiretroviral Therapy in HIV Elite Controllers: An International HIV Controller Collaboration|
|Authors:||Boufassa, Faroudy;Lechenadec, Jérome;Meyer, Laurence;Costagliola, Dominique;Hunt, Peter W.;Pereyra, Florencia;Deeks, Steve;Pancino, Gianfranco;Taulera, Olivier;Lichterfeld, Mathias;Delobel, Pierre;Saez-Cirion, Asier;Lambotte, Olivier|
|subject:||Biology;Immunology;Immune Cells;T Cells;Medicine;Clinical Immunology;Epidemiology;Clinical Epidemiology;Infectious Disease Epidemiology;Infectious Diseases;Viral Diseases;HIV;HIV clinical manifestations;HIV epidemiology|
|Publisher:||Public Library of Science|
|Description:||Objective: HIV “elite controllers” (ECs) spontaneously control viral load, but some eventually require combination antiretroviral treatment (cART), due to a loss of viral control or a decline in CD4 T-cell counts. Here we studied the CD4 T-cell count dynamics after cART initiation among 34 ECs followed in U.S. and European cohorts, by comparison with chronically viremic patients (VIRs). Methods: ECs were defined as patients with at least ≥5 viral load (VL) measurements below 400 copies/mL during at least a 5-year period despite never receiving ART and were selected from the French ANRS CO18 cohort, the U.S. SCOPE cohort, the International HIV Controllers study and the European CASCADE collaboration. VIRs were selected from the ANRS COPANA cohort of recently-diagnosed (<1 year) ART-naïve HIV-1-infected adults. CD4 T-cell count dynamics after cART initiation in both groups were modelled with piecewise mixed linear models. Results: After cART initiation, CD4 T-cell counts showed a biphasic rise in VIRs with: an initial rapid increase during the first 3 months (+0.63/month), followed by +0.19/month. This first rapid phase was not observed in ECs, in whom the CD4Tc count increased steadily, at a rate similar to that of the second phase observed in VIRs. After cART initiation at a CD4 T-cell count of 300/mm3, the estimated mean CD4 T-cell gain during the first 12 months was 139/mm3 in VIRs and 80/mm3 in ECs (p = 0.048). Conclusions: cART increases CD4 T-cell counts in elite controllers, albeit less markedly than in other patients.|
|Standard no:||Boufassa, F., J. Lechenadec, L. Meyer, D. Costagliola, P. W. Hunt, F. Pereyra, S. Deeks, et al. 2014. “Blunted Response to Combination Antiretroviral Therapy in HIV Elite Controllers: An International HIV Controller Collaboration.” PLoS ONE 9 (1): e85516. doi:10.1371/journal.pone.0085516. http://dx.doi.org/10.1371/journal.pone.0085516.|
|Appears in Collections:||HMS Scholarly Articles|
Files in This Item:
Click on the URI links for accessing contents.
Items in HannanDL are protected by copyright, with all rights reserved, unless otherwise indicated.